Category: PMCPA Case of the Week

Cases selected for the AskAnzal weekly PMCPA insight newsletter

8 Mar 2026

AUTH/2839/4/16: Anonymous v Merck Sharp & Dohme β€” Diabetes nurses study day sponsorship (No breach)

Anonymous complaint alleged MSD funded speakers and effectively ran a diabetes nurses study day without clear disclosure. Panel…

8 Mar 2026

Bayer: delayed disclosure of Phase I Xofigo trial results (AUTH/2908/11/16)

PMCPA found Bayer failed to post Phase I Xofigo trial results within the required 12 months after first…

8 Mar 2026

Sanofi-Aventis & Procter & Gamble: osteoporosis nurse audit service linked to Actonel prescribing (AUTH/1902/10/06, AUTH/1903/10/06)

ABBH nurse audit programme materials linked offering an osteoporosis audit service to agreement to prescribe Actonel. Breaches of…

8 Mar 2026

AUTH/1921/11/06: Retired Hospital Doctor v Schering Health Care (LARC public advertisement) – No breach

Schering placed a LARC information feature in an M&S magazine. Complaint alleged missing progestogen safety warnings. Panel found…

8 Mar 2026

AUTH/2686/1/14: Member of the public v Bristol-Myers Squibb (Clinical Trial Disclosure – Javlor) – Out of scope / No breach

PMCPA recorded the complaint as outwith the scope of the ABPI Code (2012). No breach was found and…

8 Mar 2026

MSD wrongly attributed a transfer of value on Disclosure UK to the wrong health professional (AUTH/3141/12/18)

MSD published an incorrect Disclosure UK entry showing a health professional received congress support. Error arose from selecting…

8 Mar 2026

AUTH/2858/7/16: Health Professional v Bayer β€” alleged promotion to the public (No breach; outwith scope)

A health professional alleged promotion of a prescription medicine to the public by Bayer. The PMCPA recorded no…

8 Mar 2026

Merz v Ipsen: Dysport β€œlong-lasting effect” campaign found misleading on appeal (AUTH/3228/7/19)

After inter-company dialogue, Ipsen’s β€œDysport – a toxin with a long-lasting effect” messaging was found to imply an…

8 Mar 2026

Consilient app preview on Google Play ruled public advertising of POM (InVita D3)

Vitamin D Vitality app previews on Google Play showed InVita D3 and PI before download. Panel ruled this…

8 Mar 2026

AUTH/3491/3/21: Complainant v Sanofi β€” Suliqua off-licence promotion allegation (No breach)

Anonymous health professional alleged Sanofi promoted Suliqua for use alongside basal insulin, risking overdose. Panel found insufficient evidence…

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training